目的 研究正清风痛宁片治疗IgA肾病中等量蛋白尿的临床疗效。方法 选择156例IgA肾病中等量蛋白尿患者(尿蛋白定量1～3 g/24 h),按入院顺序号的奇偶数分组,正清风痛宁片联合缬沙坦治疗组(观察组)78例,缬沙坦治疗组(对照组)78例。治疗剂量:正清风痛宁片每次2片,3次/d,缬沙坦治疗80 mg,1次/d,服药并观察12个月,比较两组患者临床缓解率以及24 h尿蛋白定量、血肌酐、血浆白蛋白、总蛋白、血脂等临床指标的变化,并观察临床不良反应。结果 观察12个月,观察组临床缓解率高于对照组,分别为87.2%和56.4%(P＜0.01);观察组24 h尿蛋白定量为(0.42±0.36)g/24 h,明显低于对照组[(1.59±0.66)g/24 h],两组相比差异有统计学意义(P＜0.05);血浆白蛋白和总蛋白、血肌酐水平、血脂水平以及临床不良反应两组对比差异无统计学意义。结论 正清风痛宁片联合缬沙坦治疗IgA肾病中等量蛋白尿,临床缓解率高于单纯缬沙坦治疗,能更有效降低24 h尿蛋白定量,无明显不良反应。
Abstract
Objective To study the safety and efficacy of Zhengqiang Fengtongning Tablets in the treatment of IgA nephropathy with moderate amount of proteinuria. Methods 156 patients with IgA nephropathy with moderate amount of proteinuria (urine protein quantitation: 1-3 g/24 h) were randomly divided into two groups. The study group was given Zhengqiang Fengtongning Tablets with valsartan and control group was given valsartan alone for treatment. The dosage of Zhengqiang Fengtongning was 2 tablets, 3 times a day, and valsartan was 80 mg/day. Results After treatment for 6 months, the total effective rate in the study group was significantly higher than that in the control group( 87.2% vs 56.4%, P＜0.01). 24 h urinary protein in the study group was significantly lower than that in the control group(1.59±0.66, P＜0.05). There were no differences in serum albumine, serum creatinine (Scr) , total protein (TP), total cholesterol (TC), and incidence of adverse reactions between the two groups. Conclusions Zhengqiang Fengtongning Tablets combined with valsartan for the treatment of IgA nephropathy with moderate amount of proteinuria is safe and reliable, which is worthy of clinical application.
关键词
IgA肾病 /
正清风痛宁片 /
缬沙坦
Key words
IgA nephropathy /
Zhengqiang Fengtongning Tablets /
valsartan
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 张 宏.KDIGO指南解读:IgA肾病治疗[J].中国实用内科杂志,2012,32(12):925-927.
[2] 谢静远,陈 楠.IgA肾病的临床进展[J].中国实用内科杂志,2011,31(2):90-93.
[3] Samuels J A, Strippoli G F, Graig J C ,et al. Immunosuppressive treatments for immunoglobulin a nephropathy: a meta-analysis of randomized controlled trials[J]. Nephrology ,2004,9(4):177-185.
[4] 毛心辉,盛梅笑.IgA肾病中医治疗进展[J].中国中医急症,2011,20(7):1128-1130.
[5] 杨艳光,汪国翔,黄国东.IgA肾病中医诊治研究进展分析[J].内科,2012,7(5):546-548.
[6] 余仁欢.正清风痛宁片干预IgA肾病蛋白尿的临床疗效评价[J].中国中西医结合肾病杂志,2010,23(8):721-722.[7] Lee H S, Lee M S, Lee S M, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system[J]. Nephrol Dial Transplant, 2005, 20(2):342-348.
[8] Yang Y,Ohta K,Shimizu M,et al.Treatment with low-dose angiotensin-converting enzyme inhibitor(ACEI) plus angiotensin Ⅱ receptor blocker(ARB)in pediatrics patients with IgA nephrology[J].Clin Nephrol,2005,64(1):35-40.
[9] 程 悦,张静波,袁发焕.青藤碱在治疗自身免疫性疾病中的作用机制研究[J].中国中西医结合肾病杂志,2008,9(11):1025-1027.
[10] Cheng Y,Zhang J,Hou W,et al.Immunoregulatoy effects of sinomenine on the T-bet/GATA-3 ratio and Th1/ Th2 cytokine balance in the treatment of mesangial proliferative nephritis[J].Int J Immunopharmacol,2009,9(7):894-899.
[11] 王 毅,陈 正,熊 烈,等.青藤碱对肾移植大鼠急性排斥反应及T细胞增殖的影响[J].中华实用外科杂志,2004,21(5):573-574.
[12] 叶木荣,刘 良,曾元儿,等.青藤碱在大鼠体内分布与脏器毒理的关系研究[J].中国药理学通报,2001,17(1):65-69.
[13] 邹敏书,余 健,聂国明,等.IgA肾病及过敏性紫癜性肾炎患儿血清半乳糖缺乏IgA1测定的临床意义[J]. 华南国防医学杂志,2012,26(6):542-544.
[14] 吴丽丹,刘华锋,卓华钦,等.局灶-节段性肾病患者蛋白尿促肾间质纤维化的探讨[J]. 华南国防医学杂志,2013,27(7):455-458.
[15] 赵林双,向光大,乐 岭,等.糖尿病肾病患者血清抗AT1和α1受体抗体与肾小球滤过率的关系[J]. 华南国防医学杂志,2012,26(5):448-451.
PDF(603 KB)
